Use of haptoglobin genotyping in diagnosis and treatment of defective reverse cholesterol transport (RCT)
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Mar 19, 2009
app pub date -
May 14, 2008
filing date -
May 14, 2007
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
A method of determining a potential of a nondiabetic or diabetic patient to benefit from reverse cholesterol transport therapy for treatment of a vascular complication, followed by methods and compositions of treating the diagnosed vascular complications comprising determining a haptoglobin phenotype of the patient. Reverse cholesterol transport therapy includes inhibition of cholesteryl ester transport protein, such as by using the compound torcetrapib.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully